Is CJC-1295 + Ipamorelin approved as a medicine, and where?

The regulatory review of CJC-1295 + Ipamorelin is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

What is CJC-1295 + Ipamorelin studied for?

Research has examined Component-level GHRH and GHS-R1a pharmacology (see linked monographs). Being studied for an area does not mean it is proven or approved for it.

Does CJC-1295 + Ipamorelin have human clinical trials?

The evidence review of CJC-1295 + Ipamorelin is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Peptide Blends

CJC-1295 + Ipamorelin

Name: CJC-1295 + Ipamorelin
Creator: PeptideInfo Wiki editorial collective
Published: 2026-10-07

CJC-1295 / Ipamorelin stack; CJC-1295 and Ipamorelin blend; Ipamorelin + CJC Blend; GH Synergy Blend; CJC-1295 (no DAC) & Ipamorelin; Pre-Mixed GH Secretagogue Stack

3 min read · Updated October 7, 2026 · 7 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

In brief · TL;DR

Source record — verification pending

Vendor GH stack of CJC-1295 + ipamorelin with no controlled combo clinical data. Evidence is component-wise only. Flag DAC vs no-DAC: daily-injection marketing usually implies Mod GRF (no DAC), which must not borrow Teichman 2006 DAC monotherapy numbers without disclaimer. Not approved; WADA S2-related.

Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.

Trade stack / co-lyophilisate — GHRH analogue + selective ghrelin/GHS-R1a agonist; not a covalent conjugate
No controlled human (or identified animal) combination RCT for this exact pair (2026-10-07 dossier)
DAC (long-acting, Teichman 2006) vs no-DAC / Mod GRF 1-29 (short-acting) must be distinguished — vendor stacks usually match no-DAC schedules
Component pages carry the real evidence: cjc-1295 and ipamorelin
PeptideGuide fda-approved source-label on related stubs is quarantined — not PeptideInfo's conclusion

↓ Read the full referenced entry below

CJC-1295 + ipamorelin is a common commercial stack pairing a GHRH analogue with a selective GHS-R1a agonist — not a new molecule. No controlled human combination study was identified. Most marketed vials likely contain short-acting no-DAC / Mod GRF 1-29 despite the strongest CJC human PK study describing the long-acting DAC form.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents6

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). Visible but noindexed. Editorial lane: scope-review-blend.

No controlled human combination data

No published controlled human study was identified in which CJC-1295 and ipamorelin were given together and a clinical or pharmacologic outcome measured. Vendor synergy, “GH stack” doses, and body-composition claims are not evidence. See component monographs for what is actually known.

Section 1 of 6What this stack means

What this stack means

CJC-1295 + ipamorelin is a catalog / vendor name for co-administering (often co-lyophilizing) two research peptides:

Component	Role	Existing monograph
CJC-1295	GHRH(1-29) analogue (DAC or no-DAC / Mod GRF)	Limited/early human data — not approved
Ipamorelin	Selective GHS-R1a (ghrelin receptor) agonist	Limited/early human data — not approved

There is no CAS for the blend. Mechanistic rationale (GHRH receptor + GHS-R1a → GH) is a hypothesis from receptor biology and older GHRH+GHRP literature — not proof for this product.

Legacy slugs ipa-morelin and ghrh-ghrp-blend permanently redirect here. Related but different stack: ghrp-2-cjc-blend (GHRP-2, not ipamorelin).

Section 2 of 6DAC vs no-DAC (critical)

DAC vs no-DAC (critical)

CJC-1295 is sold in two chemically different forms:

Form	Half-life (reported)	Strongest human reference	Typical vendor “daily stack” fit?
With DAC (DAC:GRF)	~5.8–8.1 days (Teichman 2006)	PMID 16352683 — GH↑ / IGF-1↑ after SC doses	Poor match for daily multi-shot marketing
Without DAC / Mod GRF 1-29	~30 minutes	No separate approved therapeutic RCT in the component monograph	Usual match for daily-injection blend marketing

Rules for readers:

Ask which form a vial contains (COA / DAC moiety).
Do not transfer Teichman 2006 DAC monotherapy hormone curves to a no-DAC blend without an explicit disclaimer.
PubChem: with-DAC CID 91971820; without-DAC CID 91976842; ipamorelin CID 9831659.

Section 3 of 6Component evidence (pointer only)

Component evidence (pointer only)

CJC-1295 with DAC — Teichman et al., 2006 (PMID 16352683)

Two randomised placebo-controlled ascending-dose studies in healthy adults. Single doses raised GH ~2–10× for ≥6 days and IGF-1 ~1.5–3× for 9–11 days; multiple doses kept IGF-1 above baseline up to 28 days. Endpoints were hormones, not body composition, sleep, or recovery.

Ipamorelin

Early work (Raun 1998) describes selective GH release with minimal ACTH/cortisol/prolactin. Human PK/PD (Gobburu 1999): terminal half-life ~2 h; one GH pulse. The only published efficacy RCT (postoperative ileus, Beck 2014 / NCT00672074) missed its primary endpoint. Never approved; WADA S2-related (see component page).

Combination search (2026-10-07)

PubMed “CJC-1295 AND ipamorelin” returned narrative/doping/sports reviews and noise — no primary combination study. No CT.gov registration for the pair was identified.

Section 4 of 6Claims vs evidence

Claims vs evidence

Claim	Assessment
Stack = GHRH analogue + GHS-R1a agonist	Partially supported as a trade definition
Proven synergistic GH release for the pair	Not verified
Teichman 2006 proves the blend	False transfer — DAC monotherapy only
Ipamorelin “approved” / “safe HGH alternative”	False as approval; ileus RCT missed primary
PeptideGuide “fda-approved” on GH Synergy Blend source snapshot	Source-label error — quarantined
Fixed clinical dose / IU scheme	Reject
Own CAS for the blend; WADA-allowed	False

Section 5 of 6Related pages

CJC-1295, Ipamorelin
Legacy slugs ipa-morelin and ghrh-ghrp-blend permanently redirect to this page
Sermorelin (related GHRH fragment; separate from this stack page)

Section 6 of 6What this page intentionally omits

What this page intentionally omits

Any dose, IU schedule, or reconstitution protocol
Synergy percentages or body-recomposition figures
PeptideGuide dosing/safety imports as facts

References7

References

1.
Prolonged stimulation of growth hormone and IGF-I by CJC-1295 (with DAC) — Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism, 2006. source
2.
Ipamorelin — selective GH secretagogue (Raun 1998) source
3.
Ipamorelin PK/PD (Gobburu 1999) source
4.
Ipamorelin postoperative ileus RCT — primary endpoint not met — Beck DE, et al., 2014. source
5.
NCT00672074 — ipamorelin ileus trial source
6.
PeptideInfo — CJC-1295 source
7.
PeptideInfo — Ipamorelin source

Frequently asked questions4

Frequently asked questions

What is CJC-1295 + Ipamorelin?: CJC-1295 + ipamorelin is a common commercial stack pairing a GHRH analogue with a selective GHS-R1a agonist — not a new molecule. No controlled human combination study was identified. Most marketed vials likely contain short-acting no-DAC / Mod GRF 1-29 despite the strongest CJC human PK study describing the long-acting DAC form.
Is CJC-1295 + Ipamorelin approved as a medicine, and where?: The regulatory review of CJC-1295 + Ipamorelin is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is CJC-1295 + Ipamorelin studied for?: Research has examined Component-level GHRH and GHS-R1a pharmacology (see linked monographs). Being studied for an area does not mean it is proven or approved for it.
Does CJC-1295 + Ipamorelin have human clinical trials?: The evidence review of CJC-1295 + Ipamorelin is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of CJC-1295 + Ipamorelin is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.

References

Frequently asked questions

Related in Peptide Blends